Status | Study |
RECRUITING |
Study Name: Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia Condition: Date: 2023-03-21 |
Active, not recruiting |
Study Name: Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Condition: Neurofibromatosis 1 Cutaneous Neurofibrom Date: 2017-03-08 Interventions: Drug: Diclofenac Sodium Follow |
Recruiting |
Study Name: Photodynamic Therapy for Benign Dermal Neurofibromas Condition: NEUROFIBROMATOSIS 1 Date: 2016-03-25 Interventions: Procedure: PDT Treatment Drug: Levulan Kerastick |
Recruiting |
Study Name: Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Condition: Neurofibromatosis 1 Plexiform Neurofibrom Date: 2015-09-05 |
Recruiting |
Study Name: Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Condition: Neurofibromatosis Type 1 Plexiform Neurof Date: 2015-06-12 Interventions: Other: Acceptance and Commitment Therapy (ACT) Acceptance and Commitment Therapy (ACT), a newer generati |
Recruiting |
Study Name: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery Condition: Neurofibromatosis Type 1 Plexiform Neurof Date: 2015-04-02 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas Condition: Plexiform Neurofibromas Date: 2014-06-25 Interventions: Drug: Imatinib Mesylate oral administration Other Na |
Active, not recruiting |
Study Name: Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) Condition: Neurofibromatoses Date: 2012-09-05 Interventions: Drug: Levulan (5-aminolevulinic acid) uptake. |
Active, not recruiting |
Study Name: How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem Condition: Neurofibromatosis Type 1 Date: 2012-06-21 |
Suspended |
Study Name: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Plexifo Date: 2011-07-25 Interventions: Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age > |